The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities
- 5 January 2010
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 19 (2) , 295-304
- https://doi.org/10.1517/13543780903540214
Abstract
(2010). The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opinion on Investigational Drugs: Vol. 19, No. 2, pp. 295-304. doi: 10.1517/13543780903540214Keywords
This publication has 58 references indexed in Scilit:
- Current perspective: Bevacizumab in colorectal cancer – A time for reappraisal?European Journal Of Cancer, 2009
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLJournal of Clinical Oncology, 2009
- Vascular disrupting agents in clinical developmentBritish Journal of Cancer, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Vascular disrupting agentsBioorganic & Medicinal Chemistry, 2006
- Vascular‐targeting therapies for treatment of malignant diseaseCancer, 2004
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Tumour necrosis factor-α plasma levels after flavone acetic acid administration in man and mouseEuropean Journal Of Cancer, 1993
- Angiogenic attack as a therapeutic strategy for cancerRadiotherapy and Oncology, 1991
- Flavone acetic acid—Preclinical and clinical activityEuropean Journal of Cancer and Clinical Oncology, 1989